The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow IPOs

By The Online Investor Staff, updated Fri., Oct. 9, 6:30 AM

Slide #2. CytomX Therapeutics, Inc. Initial Public Offering

Company: CytomX Therapeutics, Inc.
Proposed Symbol: CTMX
Shares Offered: 6,666,667
Price Per Share: $12.00
Over-Allotment: 1,000,000
Description: CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at an initial public offering price of $12 per share, before underwriting discounts and commissions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX. The shares are expected to begin trading on the NASDAQ Global Select Market on October 8, 2015 under the ticker symbol "CTMX."

IPOs: CytomX Therapeutics, Inc.

October 9, 2015    6:30 AM Eastern

IPOs | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.